Your Help is Needed to Fund the MIT Parkinson's Initiative. Please Donate or Fundraise Today.


MIT Takes on Parkinson's
Nanotechnology + Dream Team = Results.
  Apr 24 2019 . Cambridge, MA, USA

The Dream Team of researchers at MIT is paving the way for revolutionary breakthroughs in Parkinson's research - but we need your help to make it happen!

  

Cure Now: PD is working with MIT in Cambridge, MA on a Parkinson’s research initiative that is unique, that differs from existing approaches, that potentially fills a gap in existing research – an “unmet need” - using nanotechnology and MIT-specific tools and approaches that are found nowhere else.

This project ties together some of the world’s most productive research labs at MIT in an unprecedented collaboration between scientists that have already produced outcomes that are second-to-none. Simply stated, these scientists are at the top of their fields, and will now join together as world-class researchers to do “something transformative” for Parkinson’s. It’s an exciting time.

Details:

In December 2018, two decades of research starting in the Langer Lab at MIT resulted in FDA approval of Inbrija, the first approved inhaled levodopa powder for Parkinson’s patients.

This same lab – led by the “Edison of Medicine”, Robert Langer – is now in collaboration with other leading research labs at MIT and poised to begin a major research effort to take Parkinson’s research to the next level.

This MIT initiative is unlike other initiatives as it aims to develop new drugs, new scanning techniques and new drug delivery devices that are designed to circumvent the blood-brain barrier and treat the areas of the brain directly affected by PD.

If you or someone you know has PD, you may be frustrated with the pace of research. We believe existing research deserves our support, BUT WE ALSO BELIEVE FUNDING OUT OF THE BOX RESEARCH IS IMPERATIVE. The Parkinson’s Research Initiative at MIT is just that.

 

Posted by CureNow:PD





Join Us as We Make an Impact
We're All In This Together. Please Join Us!